XRTX — XORTX Therapeutics Share Price
0.000.00%
Last trade - 00:00- CA$4.66m
- CA$2.11m
- 17
- 30
- 26
- 12
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.17 | ||
| Price to Tang. Book | 1.24 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -123.41% | ||
| Return on Equity | -83.06% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 38.88 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
Directors
- Bruce Rowlands NEC
- Allen Davidoff PRE
- Amar Keshri CFO
- David MacDonald CTO
- Stephen Haworth OTH
- Brian Mangal OTH
- Alan Moore OTH
- Raymond Pratt DRC (70)
- William Farley IND (66)
- Ian Klassen IND (54)
- Jacqueline Le Saux IND
- Paul Van Damme IND (70)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 31st, 2011
- Public Since
- September 30th, 2015
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 3,788,246
- Address
- 3710 - 33rd Street NW, CALGARY, T2L 2M1
- Web
- https://www.xortx.com/
- Phone
- +1 4034557727
- Contact
- Allen Davidoff
- Auditors
- Smythe LLP
Upcoming Events for XRTX
XORTX Therapeutics Inc Annual Shareholders Meeting
Q3 2025 XORTX Therapeutics Inc Earnings Release
Similar to XRTX
Hemostemix
TSX Venture Exchange
Innovotech
TSX Venture Exchange
KDA
TSX Venture Exchange
Marvel Biosciences
TSX Venture Exchange
Medicure
TSX Venture Exchange
FAQ
What is the XORTX Therapeutics share price?
As of Today at 24:11 UTC, shares in XORTX Therapeutics are trading at CA$1.44. This share price information is delayed by 15 minutes.
How has the XORTX Therapeutics share price performed this year?
Shares in XORTX Therapeutics last closed at CA$1.44 and the price had moved by -57.01% over the past 365 days. In terms of relative price strength the XORTX Therapeutics share price has underperformed the Toronto Stock Exchange 300 Composite Index by -62.82% over the past year.
What are the analyst and broker recommendations for XORTX Therapeutics?
The overall consensus recommendation for XORTX Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the XORTX Therapeutics dividend yield?
XORTX Therapeutics does not currently pay a dividend.
Does XORTX Therapeutics pay a dividend?
XORTX Therapeutics does not currently pay a dividend.
When does XORTX Therapeutics next pay dividends?
XORTX Therapeutics does not currently pay a dividend.
How do I buy XORTX Therapeutics shares?
To buy shares in XORTX Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of XORTX Therapeutics?
As of the previous close price of CA$1.44, shares in XORTX Therapeutics had a market capitalisation of CA$5.46m.
Where are XORTX Therapeutics shares listed?
Here are the trading details for XORTX Therapeutics:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: XRTX
What kind of share is XORTX Therapeutics?
Based on an overall assessment of its quality, value and momentum XORTX Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a XORTX Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in XORTX Therapeutics is CA$81.00. That is 5525% above the last closing price of CA$1.44.
Analysts covering XORTX Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.52 for the next financial year.
Find out moreWhat is the trend in the XORTX Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like XORTX Therapeutics. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -28.98%.
As of the last closing price of CA$1.44, shares in XORTX Therapeutics were trading -20.39% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the XORTX Therapeutics PE Ratio?
The XORTX Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$1.44.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of XORTX Therapeutics?
XORTX Therapeutics' management team is headed by:
- Bruce Rowlands - NEC
- Allen Davidoff - PRE
- Amar Keshri - CFO
- David MacDonald - CTO
- Stephen Haworth - OTH
- Brian Mangal - OTH
- Alan Moore - OTH
- Raymond Pratt - DRC
- William Farley - IND
- Ian Klassen - IND
- Jacqueline Le Saux - IND
- Paul Van Damme - IND